azd-0424
Small moleculeexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2012 (NCT01668550)
Timeline
2010s
- Jan 1, 2012
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Tyrosine-protein kinase SRCINHIBITOR
SRC inhibitor
- Tyrosine-protein kinase ABLINHIBITOR
ABL1 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CC(=O)N1CCN(CCOc2cc(OC(C)C)c3c(Nc4c(Cl)cnc5c4OCO5)ncnc3c2)CC1- Mol. weight
- 529 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5314408 ↗
- ChEMBLCHEMBL3545177 ↗
Also known as
- azd0424
- azd0424
- azd-0424
- azd-0424
- azd-0424
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01668550 | Phase 1 | Oct 1, 2012 | Cancer Research UK, University of Oxford |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cancer Research UK | Academic/Hospital | 1 | 1 | 1 | 2012 |
| University of Oxford | Academic/Hospital | 1 | 0 | 1 | 2012 |
2 organizations
Page 1 / 1